2006
DOI: 10.1016/s0140-6736(06)68350-5
|View full text |Cite|
|
Sign up to set email alerts
|

Donepezil in patients with severe Alzheimer's disease: double-blind, parallel-group, placebo-controlled study

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

10
257
0
3

Year Published

2007
2007
2018
2018

Publication Types

Select...
9

Relationship

0
9

Authors

Journals

citations
Cited by 339 publications
(270 citation statements)
references
References 26 publications
10
257
0
3
Order By: Relevance
“…Both are current therapies for Alzheimer's disease and have been shown to improve cognitive ability in Alzheimer's disease patients (Burns et al, 1999;Winblad et al, 2001Winblad et al, , 2006Peskind et al, 2006;Takeda et al, 2006). In the present study, both of these compounds also increased the distance moved in response to the acoustic stimulus in a similar manner to rolipram.…”
Section: Discussionsupporting
confidence: 67%
“…Both are current therapies for Alzheimer's disease and have been shown to improve cognitive ability in Alzheimer's disease patients (Burns et al, 1999;Winblad et al, 2001Winblad et al, , 2006Peskind et al, 2006;Takeda et al, 2006). In the present study, both of these compounds also increased the distance moved in response to the acoustic stimulus in a similar manner to rolipram.…”
Section: Discussionsupporting
confidence: 67%
“…A floor effect of a test exists if more than 15% of the respondents achieved the minimum score of the test (McHorney and Tarlov, 1995), and therefore the tests are not useful in testing cognitive function in patients with severe dementia. The SIB has been used for evaluating the effect of donepezil treatment on cognition in patients with dementia in several large RCT (Winblad et al, 2006;Feldman et al, 2001), and has been found to be able to detect changes in cognitive function over time in a group of patients.…”
Section: The Validity and Reliability Of The Norwegian Version Of Thementioning
confidence: 99%
“…Dysfunction of cholinergic neurotransmission may contribute to the development of amyloid plaque pathology (Caccamo et al, 2006) and toxic soluble amyloid-b (Ab) disrupts the cholinergic neurotransmission (Bales et al, 2006). Moreover, acetylcholinesterase (AChE) inhibitors, such as donepezil, improve cognitive function in AD patients to some extent (Lane et al, 2004;Petersen et al, 2005;Winblad et al, 2006). Taken altogether, supporting cholinergic neurotransmission is deemed to be a promising strategy for AD therapy, especially for patients in the early stage of the disease, when massive and irreversible brain atrophy has not yet taken place.…”
Section: Introductionmentioning
confidence: 99%